Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC-NDCirculation reports

Early Vericiguat Initiation After First Hospitalization for Heart Failure With Reduced Ejection Fraction: A Multicenter Observational Study From the VERIFY-HF Registry and Institutional Cohorts.

3 more authors
11 affiliations
  1. 1Division of Cardiology, Department of Medicine, Kindai University Faculty of Medicine Osaka Japan.
  2. 2Department of Cardiology, Tokyo Women's Medical University Tokyo Japan.
  3. 3Division of Cardiology, Department of Internal Medicine, Iwate Medical University Iwate Japan.
  4. 4Department of Cardiology, Hyogo Prefectural Awaji Medical Center Hyogo Japan.
  5. 5Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine Tokyo Japan.
  6. 6Data Science Course, Juntendo University Tokyo Japan.
  7. 7Department of Cardiology, Keio University School of Medicine Tokyo Japan.
  8. 8Department of Cardiovascular Medicine, Kitasato University School of Medicine Kanagawa Japan.
  9. 9Department of Cardiology, Tokai University School of Medicine Kanagawa Japan.
  10. 10Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center Osaka Japan.
  11. 11Department of Cardiovascular Medicine, Nara Medical University Nara Japan.

Abstract

Background

Hospitalization for the first episode of heart failure with reduced ejection fraction (HFrEF) represents an important opportunity to initiate evidence-based therapies. In this study, we aimed to clarify the role of vericiguat after first hospitalization for HFrEF in routine clinical practice.Methods and results

This multicenter retrospective cohort study included patients with HFrEF at their first hospitalization between June 2021 and September 2023 identified from the nationwide Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat registry (vericiguat group, n=104) and 2 institutional databases (control group, n=206) (mean age, 67 years; 71% male). The primary endpoint was a composite of cardiovascular death or HF rehospitalization within 1 year. In inverse probability of treatment weighting-adjusted Cox models, vericiguat use was associated with a lower risk of the primary endpoint, compared with controls (hazard ratio, 0.26; 95% confidence interval, 0.08-0.81). Sensitivity analysis using alternative weighting methods and a doubly robust model yielded consistent results.Conclusions

In this real-world Japanese cohort of patients at first hospitalization for HFrEF, vericiguat initiation during index hospitalization was associated with a lower risk of cardiovascular death or HF rehospitalization after discharge. The observed association was directionally consistent with previous trials and pooled analyses, suggesting a potential benefit for this intermediate real-world population.

Related

  1. Safety and tolerability of rapid vericiguat initiation and titration alongside GDMT optimization in HFrEF: a prospective cohort study.
    Lu Gao, Botao Shen, Haoxuan Chu +2
    Journal of cardiothoracic surgeryPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC
  2. Nutritional risk, inflammation, and hospitalization after hemodialysis initiation
    Hikaru Uematsu, Tatsunori Toida, Yuri Tanaka +1
    Renal FailurePeer-reviewedCC BY 4.0Full textGeneral medicineDOAJPMC
  3. Changes in hepatic functional reserve and renal function during hospitalization in patients with chronic liver disease : A retrospective observational study of inpatient rehabilitation
    Rikito Zaiki, Yoshiyuki Ida, Akiyuki Okamoto +3
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Hospitalization outcomes following planned versus unplanned dialysis initiation: a comparative study of hemodialysis and peritoneal dialysis modalities
    Selene T. Y. Teoh, Sri F. B. B. Saifful, Janice T. Z. Ho +10
    Renal FailurePeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  5. Clinical Characteristics Associated with Mortality between Surviving and Non-surviving Adult Patients with Severe Influenza Requiring Hospitalization: An Internet-based, Prospective, Multicenter, Cohort Study in Japan
    Masafumi Seki, Akihiro Ito, Yuki Shiko +19
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthJ-STAGE
BibTeX
@article{matsuzoe2026early,
  title = {{Early Vericiguat Initiation After First Hospitalization for Heart Failure With Reduced Ejection Fraction: A Multicenter Observational Study From the VERIFY-HF Registry and Institutional Cohorts.}},
  author = {Hiroki Matsuzoe and Koichiro Matsumura and Atsushi Suzuki and Ayano Yoshida and Shohei Hakozaki and Takahito Nasu and Wataru Fujimoto and Nobuyuki Kagiyama and Yasuyuki Shiraishi and Shunsuke Ishii and Takeshi Ijichi and Koshiro Kanaoka and Shingo Matsumoto and Gaku Nakazawa and VERIFY-HF Investigators},
  journal = {Circulation reports},
  year = {2026},
  month = sep,
  doi = {10.1253/circrep.cr-26-0241},
  url = {https://europepmc.org/article/MED/43011013},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Early Vericiguat Initiation After First Hospitalization for Heart Failure With Reduced Ejection Fraction: A Multicenter Observational Study From the VERIFY-HF Registry and Institutional Cohorts.
AU  - Hiroki Matsuzoe
AU  - Koichiro Matsumura
AU  - Atsushi Suzuki
AU  - Ayano Yoshida
AU  - Shohei Hakozaki
AU  - Takahito Nasu
AU  - Wataru Fujimoto
AU  - Nobuyuki Kagiyama
AU  - Yasuyuki Shiraishi
AU  - Shunsuke Ishii
AU  - Takeshi Ijichi
AU  - Koshiro Kanaoka
AU  - Shingo Matsumoto
AU  - Gaku Nakazawa
AU  - VERIFY-HF Investigators
PY  - 2026
DA  - 2026/09/26
JO  - Circulation reports
DO  - 10.1253/circrep.cr-26-0241
UR  - https://europepmc.org/article/MED/43011013
AB  - Background  Hospitalization for the first episode of heart failure with reduced ejection fraction (HFrEF) represents an important opportunity to initiate evidence-based therapies. In this study, we aimed to clarify the role of vericiguat after first hospitalization for HFrEF in routine clinical practice.Methods and results  This multicenter retrospective cohort study included patients with HFrEF at their first hospitalization between June 2021 and September 2023 identified from the nationwide Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat registry (vericiguat group, n=104) and 2 institutional databases (control group, n=206) (mean age, 67 years; 71% male). The primary endpoint was a composite of cardiovascular death or HF rehospitalization within 1 year. In inverse probability of treatment weighting-adjusted Cox models, vericiguat use was associated with a lower risk of the primary endpoint, compared with controls (hazard ratio, 0.26; 95% confidence interval, 0.08-0.81). Sensitivity analysis using alternative weighting methods and a doubly robust model yielded consistent results.Conclusions  In this real-world Japanese cohort of patients at first hospitalization for HFrEF, vericiguat initiation during index hospitalization was associated with a lower risk of cardiovascular death or HF rehospitalization after discharge. The observed association was directionally consistent with previous trials and pooled analyses, suggesting a potential benefit for this intermediate real-world population.
SN  - 2434-0790
ER  -